Meta-analyses which included variants of MTHFR, TYMS and SLC19A1 pharmacogenes [20,21,22,23] could not definitely disregard or establish analyzed variants as MTX pharmacogenomic markers of ALL treatment. This evidence concerns the gene MTHFR and acute lymphoblastic leukemia.